Sign in
Not yet taking people in SpainPhase 4

Compares two heart medicines, levosimendan and dobutamine, in people with weak heart pumping

Compares levosimendan and dobutamine in adults with heart failure and reduced heart pumping.

Key facts

Who runs it
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
Where
Badalona, SpainSee the site
Registry title
LEVOMEMS: Comparison of the effects of dobutamine and levosimendan in the current treatment of heart diseases.
Status
Not yet recruiting
Phase
Phase 4
People taking part
10 people, planned
Started
14 Feb 2023
Planned end
31 Jul 2025
Type of study
Interventional
Record updated
3 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure and a weak pumping heart. It compares how dobutamine and levosimendan change lung artery pressure and the amount of blood the heart pumps.

Age
Over 18 years
Sex
All
Disease stage
Heart failure with a left ventricular ejection fraction (FEVI) under 35% on an echocardiogram in the last 6 months. NYHA class above III, with limited function despite optimized heart failure and diuretic treatment. A hospital stay or decompensation treated as an outpatient with a diuretic in the last six months, which led to the CardioMEMS device.
Earlier treatment
Optimized heart failure treatment and a diuretic, as above.

Main reasons for not taking part

  • Creatinine clearance under 20 ml / min
  • Systolic blood pressure under 90 mmHg
  • Women who can have children without effective contraception, or who are breastfeeding
  • Pregnancy
  • Hypersensitivity to the active ingredients or any excipient

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age> 18 years
  • FEVI <35% for echocardiography in the last 6 months
  • Functional class NYHA> III with functional impairment despite optimized treatment of HF and diuretic with admission or decompensation treated on an outpatient basis with diuretic in the last six months that motivate the implementation of the CardioMEMS device
  • Signing of informed consent

Who cannot take part

  • Hypersensitivity to the active ingredients or to any of the excipients
  • Creatinine clearance <20 ml / min
  • Presión arterial sistólica <90 mmHg
  • Pregnant or fertile women (who are in the period between menorrhagia and menopause) without effective contraceptive coverage, or in breastfeeding

Where in Spain

  • Hospital Germans Trias i PujolBadalona, SpainNot yet recruiting

About the trial

What the trial wants to find out

To assess the change in the pulmonary arterial pressure and the cardiac output with levosimendan or dobutamine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
LEVOMEMS: Comparison of the Hemodynamic Profile of Dobutamine and Levosimendan in the Current Therapeutic Context
Plain-language title
Compares two heart medicines, levosimendan and dobutamine, in people with weak heart pumpingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 December 2024